Bevacizumab in combination with IFN-alfa in metastatic renal cell carcinoma: the AVOREN trial.

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F12%3A33140649" target="_blank" >RIV/61989592:15110/12:33140649 - isvavai.cz</a>

Result on the web

<a href="http://dx.doi.org/10.1586/era.12.103" target="_blank" >http://dx.doi.org/10.1586/era.12.103</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1586/era.12.103" target="_blank" >10.1586/era.12.103</a>

Result language

angličtina

Original language name

Bevacizumab in combination with IFN-alfa in metastatic renal cell carcinoma: the AVOREN trial.

Original language description

Metastatic renal cell carcinoma (mRCC) is tumor resistant to all cytotoxic agents. During the last decade, effective targeted therapies emerged including sunitinib, pazopanib and the combination of bevacizumab with IFN-alfa. The use of bevacizumab plus IFN-alfa combination in mRCC is supported by the AVOREN trial. Although the primary end point of the AVOREN trial was overall survival, progression-free survival was used to evaluate efficacy and served as the basis of regulatory submission owing to the advent of targeted agents that probably resulted in the prolongation of overall survival in both experimental and control arms. The doubling of median progression-free survival in the AVOREN trials (from 5.4 to 10.2 months) is remarkably similar comparedwith the results of Phase III trials with sunitinib and pazopanib. Bevacizumab plus IFN-alfa is the only combined regimen currently used in mRCC and serves as a comparator in the trials combining bevacizumab with other agents.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2012

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Expert Review of Anticancer Therapy

ISSN

1473-7140

e-ISSN

—

Volume of the periodical

12

Issue of the periodical within the volume

10

Country of publishing house

GB - UNITED KINGDOM

Number of pages

10

Pages from-to

1253-1261

UT code for WoS article

—

EID of the result in the Scopus database

—